Cop 1 as a candidate drug for multiple sclerosis

  • D. Teitelbaum
  • R. Arnon
  • M. Sela
Conference paper


Copolymer 1 (Cop 1), a synthetic copolymer of amino acids, is very effective in suppression of experimental autoimmune encephalomyelitis (EAE), the animal model for multiple sclerosis (MS). Cop 1 was found incapable of inducing EAE, yet it suppressed EAE in a variety of animal species, including primates. The immunological cross-reaction between the myelin basic protein (MBP) and Cop 1 serves as the basis for the suppressive activity of Cop 1 in EAE, by the induction of antigen-specific suppressor cells and competition with MBP for binding to major histocompatibility complex (MHC) molecules. Clinical trials with Cop 1, both Phase II and Phase III, were performed in relapsing-remitting (E-R) patients. The latter, a two-year multi-center double blind trial with 251 participating patients was conducted at 11 leading medical centers in the USA. It demonstrated a significant beneficial effect of Cop 1 in both diminishing the rate of exacerbations and improving the clinical status. The side effects of Cop 1 were only minimal. The cumulative results indicate that Cop 1 is a promising candidate drug for multiple sclerosis.


Multiple Sclerosis Major Histocompatibility Complex Multiple Sclerosis Patient Myelin Basic Protein Experimental Allergic Encephalomyelitis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Abramsky O, Teitelbaum D, Arnon R (1977) Effect of a synthetic polypeptide (Cop 1) on patients with multiple sclerosis and with acute disseminated encephalomyelitis. J Neurol Sci 31: 433–438PubMedCrossRefGoogle Scholar
  2. Aharoni R, Teitelbaum D, Arnon R (1993) T-suppressor hybridomas and IL-2 dependent lines induced by copolymer 1 or by spinal cord homogenate down regulate experimental allergic encephalomyelitis. Eur J Immunol 23: 17–25PubMedCrossRefGoogle Scholar
  3. Aharoni R, Teitelbaum D, Sela M, Arnon R (1996) Copolymer 1 induces suppressor T cells of the Th2 type. J Neurol 243 [Suppl 2]: S17Google Scholar
  4. Arnon R (1981) Experimental allergic encephalomyelitis-susceptibility and suppression. Immunol Rev 55: 5–30PubMedCrossRefGoogle Scholar
  5. Bernard CCA, Kerlero de Rosbo N (1992) Multiple sclerosis an autoimmune disease of multifunctional etiology. Curr Opin Immunol 2: 760–765CrossRefGoogle Scholar
  6. Ben-Nun A, Mendel I, Bakimeer R, Fridkis-Hareli M, Teitelbaum D, Arnon R, Sela M, Kerlero de Rosbo N (1996) The autoimmune reactivity to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis is potentially pathogenic: effect of Copolymer 1 on MOG-induced disease. J Neurol 43 [Suppl 1]: S14–S22CrossRefGoogle Scholar
  7. Bornstein MB, Miller AJ, Teitelbaum D, Arnon R, Sela M (1982) Multiple sclerosis: trial of a synthetic polypeptide. Ann Neurol 11: 317–319PubMedCrossRefGoogle Scholar
  8. Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, Keilson M, Merriam A, Wassertheil-Smoller S, Spada V, Weiss W, Arnon R, Jacobsohn I, Teitelbaum D, Sela M (1987) A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 317: 408–414PubMedCrossRefGoogle Scholar
  9. Fridkis-Hareli, M, Teitelbaum D, Gurevich E, Pecht I, Brautbar C, Oh Joong K, Brenner T, Arnon R, Sela M (1994) Direct binding of myelin basic protein and synthetic copolymer 1 to class II major histocompatibility complex molecules on living antigen presenting cells-specificity and promiscuity. Proc Natl Acad Sci US 91: 4872–4876CrossRefGoogle Scholar
  10. Johnson KP, Brooks, BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Pannitch HS, Rose JW, Schiffer RB, Vollmer T, Weiner LP, Wolinsky JC (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing — remitting multiple sclerosis. Results of a phase III multicenter double blind, placebo-controlled trial. Neurology 1: 65–70Google Scholar
  11. Johnson KP, The Copolymer 1 Multiple Sclerosis Study Group (1996) Extended report of the positive multicenter phase III trial of copolymer 1 for the treatment of relapsing remitting multiple sclerosis. Neurology 46: A406Google Scholar
  12. Keith AB, Arnon R, Teitelbaum D, Caspary EA, Wisniewski HM (1979) The effect of Cop 1, a synthetic polypeptide, on chronic relapsing experimental allergic encephalomyelitis in guinea pigs. J Neurol Sci 42: 267–274PubMedCrossRefGoogle Scholar
  13. Lando Z, Teitelbaum D, Arnon R (1979) Effect of cyclophosphamide on suppressor cell activity in mice unresponsive to EAE. J Immunol 123: 2156–2160PubMedGoogle Scholar
  14. Lando Z, Teitelbaum D, Arnon R (1981) The immunological response in mice unresponsive to experimental allergic encephalomyelitis. J Immunol 126: 1526–1528PubMedGoogle Scholar
  15. Lando Z, Dori Y, Teitelbaum D, Arnon R (1981) Unresponsiveness to experimental allergic encephalomyelitis in mice-replacement of suppressor cells by a soluble factor. J Immunol 127: 1915–1919PubMedGoogle Scholar
  16. Sela M, Arnon R, Teitelbaum D (1990) Suppressive activity of Cop 1 in EAE and its relevance to multiple sclerosis. Bull Inst Pasteur 88: 303–314Google Scholar
  17. Teitelbaum D, Meshorer A, Hirshfeld T, Arnon R, Sela M (1971) Suppression of experimental allergic encephalomyelitis by a synthetic basic copolymer. Eur J Immunol 1: 242–248PubMedCrossRefGoogle Scholar
  18. Teitelbaum D, Webb C, Meshorer A, Arnon R, Sela M (1973) Suppression by several synthetic polypeptides of experimental allergic encephalomyelitis induced in guinea pigs and rabbits with bovine and human basic encephalitogen. Eur J Immunol 3: 273–279PubMedCrossRefGoogle Scholar
  19. Teitelbaum D, Webb C, Bree M, Meshorer A, Arnon R, Sela M (1974) Suppression of experimental allergic encephalomyelitis in rhesus monkeys by a synthetic basic copolymer. Clin Immunol Immunopathol 3: 256–262PubMedCrossRefGoogle Scholar
  20. Teitelbaum D, Meshorer A, Arnon R (1977) Suppression of experimental allergic encephalomyelitis in baboons by Cop 1. Israel J Med Sci 13: 1038Google Scholar
  21. Teitelbaum D, Aharoni R, Arnon R, Sela M (1988) Specific inhibition of the T-cell response to myelin basic protein by the synthetic copolymer Cop 1. Proc Natl Acad Sci USA 85: 9724–9728PubMedCrossRefGoogle Scholar
  22. Teitelbaum D, Aharoni R, Sela M, Arnon R (1991) Cross reactions and specificities of monoclonal antibodies against myelin basic protein and against the synthetic copolymer 1. Proc Natl Acad Sci USA 88: 9528–9532PubMedCrossRefGoogle Scholar
  23. Teitelbaum D, Milo R, Arnon R, Sela M (1992) Synthetic copolymer 1 inhibits human T-cell lines specific for myelin basic protein. Proc Natl Acad Sci USA 89: 137–141PubMedCrossRefGoogle Scholar
  24. Teitelbaum D, Fridkis-Hareli M, Arnon R, Sela M (1996) Copolymer 1 inhibits the onset of chronic relapsing experimental autoimmune encephalomyelitis and interferes with T cell responses to encephalitogenic peptides of myelin proteolipid protein. J Neuroimmunol 64: 209–217PubMedCrossRefGoogle Scholar
  25. Waksman BH (1985) Mechanisms in multiple sclerosis. Nature 318: 104–105PubMedCrossRefGoogle Scholar
  26. Webb C, Teitelbaum D, Arnon R, Sela M (1973) In vivo and in vitro immunological cross-reactions between basic encephalitogen and synthetic basic polypeptides capable of suppressing experimental allergic encephalomyelitis. Eur J Immunol 3: 279–286PubMedCrossRefGoogle Scholar
  27. Webb C, Teitelbaum D, Herz A, Arnon R, Sela M (1976) Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids. Immunochemistry 13: 333–337PubMedCrossRefGoogle Scholar
  28. Wisniewski HM, Keith AB (1977) Chronic relapsing experimental allergic encephalomyelitis: an experimental model of multiple sclerosis. Ann Neurol 1: 144–148PubMedCrossRefGoogle Scholar
  29. Zamvil SS, Steinman L (1990) The T lymphocyte in experimental allergic encephalomyelitis. Ann Rev Immunol 8: 579–621CrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1997

Authors and Affiliations

  • D. Teitelbaum
    • 1
  • R. Arnon
    • 1
  • M. Sela
    • 1
  1. 1.Department of ImmunologyWeizmann Institute of ScienceRehovotIsrael

Personalised recommendations